{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:33:59Z","timestamp":1792503239352,"version":"4.5.0"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T00:00:00Z","timestamp":1686009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006095","name":"Helse S\u00f8r-\u00d8st RHF","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Inhibitors of the ATR kinase act as radiosensitizers through abrogating the G2 checkpoint and reducing DNA repair. Recent studies suggest that ATR inhibitors can also increase radiation-induced antitumor immunity, but the underlying immunomodulating mechanisms remain poorly understood. Moreover, it is poorly known how such immune effects relate to different death pathways such as caspase-dependent apoptosis. Here we address whether ATR inhibition in combination with irradiation may increase the presentation of hallmark factors of immunogenic cell death (ICD), and to what extent caspase activation regulates this response.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Human lung cancer and osteosarcoma cell lines (SW900, H1975, H460, U2OS) were treated with X-rays and ATR inhibitors (VE822; AZD6738) in the absence and presence of a pan-caspase inhibitor. The ICD hallmarks HMGB1 release, ATP secretion and calreticulin surface-presentation were assessed by immunoblotting of growth medium, the <jats:italic>CellTiter-Glo<\/jats:italic> assay and an optimized live-cell flow cytometry assay, respectively. To obtain accurate measurement of small differences in the calreticulin signal by flow cytometry, we included normalization to a barcoded control sample.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Extracellular release of HMGB1 was increased in all the cell lines at 72 hours after the combined treatment with radiation and ATR inhibitors, relative to mock treatment or cells treated with radiation alone. The HMGB1 release correlated largely \u2013 but not strictly \u2013 with loss of plasma membrane integrity, and was suppressed by addition of the caspase inhibitor. However, one cell line showed HMGB1 release despite caspase inhibition, and in this cell line caspase inhibition induced pMLKL, a marker for necroptosis. ATP secretion occurred already at 48 hours after the co-treatment and did clearly not correlate with loss of plasma membrane integrity. Addition of pan-caspase inhibition further increased the ATP secretion. Surface-presentation of calreticulin was increased at 24-72 hours after irradiation, but not further increased by either ATR or caspase inhibition.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>These results show that ATR inhibition can increase the presentation of two out of three ICD hallmark factors from irradiated human cancer cells. Moreover, caspase activation distinctly affects each of the hallmark factors, and therefore likely plays a dual role in tumor immunogenicity by promoting both immunostimulatory and -suppressive effects.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1138920","type":"journal-article","created":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T16:15:56Z","timestamp":1686068156000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Immunogenic cell death after combined treatment with radiation and ATR inhibitors is dually regulated by apoptotic caspases"],"prefix":"10.3389","volume":"14","author":[{"given":"Adrian","family":"Eek Mariampillai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sissel","family":"Hauge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karoline","family":"Kongsrud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randi G.","family":"Sylju\u00e5sen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(95)97825-L","article-title":"Differential sensitivity of p53(-) and p53(+) cells to caffeine-induced radiosensitization and override of G2 delay","volume":"55","author":"Powell","year":"1995","journal-title":"Cancer Res"},{"key":"B2","article-title":"Abrogation of the G2 checkpoint results in differential radiosensitization of G1 checkpoint-deficient and G1 checkpoint-competent cells","volume":"55","author":"Russell","year":"1995","journal-title":"Cancer Res"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2016.12.007","article-title":"Coupling of homologous recombination and the checkpoint by ATR","volume":"65","author":"Buisson","year":"2017","journal-title":"Mol Cell"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206682","article-title":"DNA Damage checkpoint control in cells exposed to ionizing radiation","volume":"22","author":"Iliakis","year":"2003","journal-title":"Oncogene"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1207528","article-title":"Cell death by mitotic catastrophe: a molecular definition","volume":"23","author":"Castedo","year":"2004","journal-title":"Oncogene"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers9050041","article-title":"Targeting the ATR-CHK1 axis in cancer therapy","volume":"9","author":"Rundle","year":"2017","journal-title":"Cancers"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2015.00070","article-title":"Targeting lung cancer through inhibition of checkpoint kinases","volume":"6","author":"Sylju\u00e5sen","year":"2015","journal-title":"Front Genet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"100017","DOI":"10.1016\/j.crphar.2021.100017","article-title":"Progress towards a clinically-successful ATR inhibitor for cancer therapy","volume":"2","author":"Barnieh","year":"2021","journal-title":"Curr Res Pharmacol Drug Discovery"},{"key":"B9","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ctro.2018.06.001","article-title":"PATRIOT: a phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours","volume":"12","author":"Dillon","year":"2018","journal-title":"Clin Trans Radiat Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2022.04.003","article-title":"Radiation therapy-induced remodeling of the tumor immune microenvironment","volume":"86","author":"Charpentier","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.971959","article-title":"Enhancing anti-tumour innate immunity by targeting the DNA damage response and pattern recognition receptors in combination with radiotherapy","volume":"12","author":"Chan Wah Hak","year":"2022","journal-title":"Front Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.4161\/onci.28518","article-title":"Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death","volume":"3","author":"Golden","year":"2014","journal-title":"Oncoimmunology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/s41419-020-03221-2","article-title":"Detection of immunogenic cell death and its relevance for cancer therapy","volume":"11","author":"Fucikova","year":"2020","journal-title":"Cell Death disease"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20133212","article-title":"Tumor microenvironment as a \u201cGame changer\u201d in cancer radiotherapy","volume":"20","author":"Jarosz-Biej","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B15","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","article-title":"Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018","volume":"25","author":"Galluzzi","year":"2018","journal-title":"Cell Death differentiation"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3380","article-title":"Immunogenic cell death and DAMPs in cancer therapy","volume":"12","author":"Krysko","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e955691","DOI":"10.4161\/21624011.2014.955691","article-title":"Consensus guidelines for the detection of immunogenic cell death","volume":"3","author":"Kepp","year":"2014","journal-title":"Oncoimmunology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1146\/annurev.iy.12.040194.005015","article-title":"Tolerance, danger, and the extended family","volume":"12","author":"Matzinger","year":"1994","journal-title":"Annu Rev Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1172\/JCI96519","article-title":"ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation","volume":"128","author":"Vendetti","year":"2018","journal-title":"J Clin Invest"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1821","article-title":"ATR inhibition potentiates the radiation-induced inflammatory tumor microenvironment","volume":"25","author":"Dillon","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000340","article-title":"ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma","volume":"8","author":"Sheng","year":"2020","journal-title":"J immunother Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abl9330","article-title":"ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer","volume":"7","author":"Hsieh","year":"2022","journal-title":"Sci Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2117321","DOI":"10.1080\/2162402X.2022.2117321","article-title":"Targeting DNA damage response components induces enhanced STING-dependent type-I IFN response in ATM deficient cancer cells and drives dendritic cell activation","volume":"11","author":"Lopez-Pelaez","year":"2022","journal-title":"Oncoimmunology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2019104036","article-title":"ATR inhibition potentiates ionizing radiation-induced interferon response via cytosolic nucleic acid-sensing pathways","volume":"39","author":"Feng","year":"2020","journal-title":"EMBO J"},{"key":"B25","doi-asserted-by":"publisher","first-page":"108080","DOI":"10.1016\/j.celrep.2020.108080","article-title":"Cell cycle checkpoints cooperate to suppress DNA- and RNA-associated molecular pattern recognition and anti-tumor immune responses","volume":"32","author":"Chen","year":"2020","journal-title":"Cell Rep"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.981332","article-title":"Caspase activation counteracts interferon signaling after G2 checkpoint abrogation by ATR inhibition in irradiated human cancer cells","volume":"12","author":"Eek Mariampillai","year":"2022","journal-title":"Front Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/978-3-319-67577-0_5","article-title":"Immunogenic and non-immunogenic cell death in the tumor microenvironment","volume":"1036","author":"Pitt","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/cdd.2013.75","article-title":"Molecular mechanisms of ATP secretion during immunogenic cell death","volume":"21","author":"Martins","year":"2014","journal-title":"Cell Death differentiation"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/emboj.2009.1","article-title":"Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death","volume":"28","author":"Panaretakis","year":"2009","journal-title":"EMBO J"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/jmcb\/mjab071","article-title":"The crosstalk between the caspase family and the cGAS\u2212STING signaling pathway","volume":"13","author":"Xiong","year":"2021","journal-title":"J Mol Cell Biol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/febs.16051","article-title":"Regulation of innate immune responses by cell death-associated caspases during virus infection","volume":"289","author":"Fang","year":"2022","journal-title":"FEBS J"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e1761","DOI":"10.1038\/cddis.2015.129","article-title":"Modulation of radiochemoimmunotherapy-induced B16 melanoma cell death by the pan-caspase inhibitor zVAD-fmk induces anti-tumor immunity in a HMGB1-, nucleotide- and T-cell-dependent manner","volume":"6","author":"Werthm\u00f6ller","year":"2015","journal-title":"Cell Death disease"},{"key":"B33","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.immuni.2008.05.013","article-title":"Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein","volume":"29","author":"Kazama","year":"2008","journal-title":"Immunity"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e1655964","DOI":"10.1080\/2162402X.2019.1655964","article-title":"Apoptotic caspases inhibit abscopal responses to radiation and identify a new prognostic biomarker for breast cancer patients","volume":"8","author":"Rodriguez-Ruiz","year":"2019","journal-title":"Oncoimmunology"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0641-5","article-title":"Tumor cells suppress radiation-induced immunity by hijacking caspase 9 signaling","volume":"21","author":"Han","year":"2020","journal-title":"Nat Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2385","article-title":"Caspase 3-mediated stimulation of tumor cell repopulation during cancer radiotherapy","volume":"17","author":"Huang","year":"2011","journal-title":"Nat Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1093\/embo-reports\/kvf198","article-title":"The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway","volume":"3","author":"Gardella","year":"2002","journal-title":"EMBO Rep"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00616.2005","article-title":"The extracellular release of HMGB1 during apoptotic cell death","volume":"291","author":"Bell","year":"2006","journal-title":"Am J Physiol Cell Physiol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1126\/science.285.5425.248","article-title":"HMG-1 as a late mediator of endotoxin lethality in mice","volume":"285","author":"Wang","year":"1999","journal-title":"Sci (New York NY)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6060(99)70182-0","article-title":"Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes","volume":"126","author":"Wang","year":"1999","journal-title":"Surgery"},{"key":"B41","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s12276-022-00736-w","article-title":"The mechanism of HMGB1 secretion and release","volume":"54","author":"Chen","year":"2022","journal-title":"Exp Mol Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20052203","article-title":"Role of HMGB1 in apoptosis-mediated sepsis lethality","volume":"203","author":"Qin","year":"2006","journal-title":"J Exp Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/cells10102550","article-title":"Caspase-dependent HMGB1 release from macrophages participates in peripheral neuropathy caused by bortezomib, a proteasome-inhibiting chemotherapeutic agent, in mice","volume":"10","author":"Tsubota","year":"2021","journal-title":"Cells"},{"key":"B44","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00280-021-04367-2","article-title":"4-(N)-Docosahexaenoyl 2\u2019, 2\u2019-difluorodeoxycytidine induces immunogenic cell death in colon and pancreatic carcinoma models as a single agent","volume":"89","author":"Hufnagel","year":"2022","journal-title":"Cancer chemother Pharmacol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/s41419-021-03997-x","article-title":"Pharmacological inhibitors of anaplastic lymphoma kinase (ALK) induce immunogenic cell death through on-target effects","volume":"12","author":"Petrazzuolo","year":"2021","journal-title":"Cell Death disease"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.1719","article-title":"Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing","volume":"5","author":"Gameiro","year":"2014","journal-title":"Oncotarget"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13153790","article-title":"Differential effects of combined ATR\/WEE1 inhibition in cancer cells","volume":"13","author":"R\u00f8dland","year":"2021","journal-title":"Cancers"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13051010","article-title":"EPHA2 interacts with DNA-PK(cs) in cell nucleus and controls ionizing radiation responses in non-small cell lung cancer cells","volume":"13","author":"Kaminskyy","year":"2021","journal-title":"Cancers"},{"key":"B49","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin exposure dictates the immunogenicity of cancer cell death","volume":"13","author":"Obeid","year":"2007","journal-title":"Nat Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12412","article-title":"Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancer","volume":"43","author":"Liu","year":"2023","journal-title":"Cancer Commun (London England)"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004306","article-title":"Harnessing radiotherapy-induced NK-cell activity by combining DNA damage-response inhibition and immune checkpoint blockade","volume":"10","author":"Patin","year":"2022","journal-title":"J immunother Cancer"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1158\/1538-7445.AM2019-2269","article-title":"ATR inhibitor M6620 enhances anti-tumor efficacy of the combination of the anti-PD-L1 antibody avelumab with platinum-based chemotherapy","volume":"79","author":"Alimzhanov","year":"2019","journal-title":"Cancer Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-042320-025136","article-title":"A tale of two checkpoints: ATR inhibition and PD-(L)1 blockade","volume":"73","author":"Ngoi","year":"2022","journal-title":"Annu Rev Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.638873","article-title":"Optimizing the treatment schedule of radiotherapy combined with anti-PD-1\/PD-L1 immunotherapy in metastatic cancers","volume":"11","author":"Kong","year":"2021","journal-title":"Front Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-020-01666-1","article-title":"Rationale of combination of anti-PD-1\/PD-L1 antibody therapy and radiotherapy for cancer treatment","volume":"25","author":"Sato","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s13014-020-01678-1","article-title":"Reprogramming the tumour microenvironment by radiotherapy: implications for radiotherapy and immunotherapy combinations","volume":"15","author":"Colton","year":"2020","journal-title":"Radiat Oncol (London England)"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.165615","article-title":"The schedule of ATR inhibitor AZD6738 can potentiate or abolish antitumor immune responses to radiotherapy","volume":"8","author":"Vendetti","year":"2023","journal-title":"JCI Insight"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1138920\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T16:16:00Z","timestamp":1686068160000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1138920\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,6]]},"references-count":57,"alternative-id":["10.3389\/fimmu.2023.1138920"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1138920","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,6]]},"article-number":"1138920"}}